第4组ITI共识报告:种植牙相关的风险与生物学并发症
本共识报告聚焦种植牙相关生物学风险与并发症,基于4篇系统综述,由工作组形成并全会通过共识声明。结论包括:诊断种植体周围炎需探诊出血(BOP)合并进行性骨吸收,BOP单独不足;增量位点种植体周围炎患病率中远期较低;种植体周围炎治疗后需个体化支持维护;高龄本身非种植禁忌,但需评估共病与自主性。
要点
- 诊断种植体周围炎需BOP加进行性骨吸收,单凭BOP不足。
- 增量位点种植体周围炎与种植体丧失的中远期患病率较低。
- 高龄非种植禁忌,但需考虑共病与自主性。
核心结论
- 诊断种植体周围炎需要BOP和进行性骨丧失同时存在。
- 增量位点种植体的种植体周围炎患病率低。
- 种植体周围炎治疗应继以个体化支持性维护。
- 老年患者种植治疗并非禁忌,但应考虑共病与自主性。
研究设计与样本
- 第4工作组基于4篇系统综述形成共识声明与推荐,经全会讨论修改后接受。
主要发现
- 单独BOP不足以诊断种植体周围炎。
- BOP单独诊断种植体周围炎的阳性预测值随人群患病率变化而异。
- 增量位点种植体在中期至长期内种植体周围炎和种植体丧失患病率低。
- 含个体化支持性维护的种植体周围炎治疗方案在5年后种植体存活率高,约四分之三种植体仍存留。
- 高龄本身不是种植治疗禁忌证。
关键数值与推荐
- 种植体周围炎诊断需BOP加进行性骨丧失。
- 增量位点种植体的种植体周围炎患病率低。
- 种植体周围炎治疗后应行个体化支持性维护。
- 高龄患者可接受种植治疗,但需评估共病与自主性。
- 接受高剂量抗骨吸收治疗的癌症患者禁忌种植。
临床怎么用
- 种植体周围炎诊断应结合BOP与进行性骨丧失,不单凭BOP。
- 种植体周围炎治疗后应安排个体化支持性维护。
- 老年患者种植前应评估共病与自主性,高龄本身不构成禁忌。
局限性
- 原文未涉及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of Working Group 4 was to address topics related to biologic risks and complications associated with implant dentistry. Focused questions on (a) diagnosis of peri-implantitis, (b) complications associated with implants in augmented sites, (c) outcomes following treatment of peri-implantitis, and (d) implant therapy in geriatric patients and/or patients with systemic diseases were addressed. MATERIALS AND METHODS: Four systematic reviews formed the basis for discussion in Group 4. Participants developed statements and recommendations determined by group consensus based on the findings of the systematic reviews. These were then presented and accepted following further discussion and modifications as required by the plenary. RESULTS: Bleeding on probing (BOP) alone is insufficient for the diagnosis of peri-implantitis. The positive predictive value of BOP alone for the diagnosis of peri-implantitis varies and is dependent on the prevalence of peri-implantitis within the population. For patients with implants in augmented sites, the prevalence of peri-implantitis and implant loss is low over the medium to long term. Peri-implantitis treatment protocols which include individualized supportive care result in high survival of implants after 5 years with about three-quarters of implants still present. Advanced age alone is not a contraindication for implant therapy. Implant placement in patients with cancer receiving high-dose antiresorptive therapy is contraindicated due to the associated high risk for complications. CONCLUSIONS: Diagnosis of peri-implantitis requires the presence of BOP as well as progressive bone loss. Prevalence of peri-implantitis for implants in augmented sites is low. Peri-implantitis treatment should be followed by individualized supportive care. Implant therapy for geriatric patients is not contraindicated; however, comorbidities and autonomy should be considered.
引用
- Heitz-Mayfield LJ, Aaboe M, Araujo M, et al. Group 4 ITI Consensus Report: Risks and biologic complications associated with implant dentistry. Clin Oral Implants Res. 2018. PMID: 30328181. doi:10.1111/clr.13307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。